| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.946 | 0.001 | 0.946 | Glutamate decarboxylase inhibitor | 0.52 0.002 DBMET00502 0.161 0.011 DBMET00494 | ||
| 0.844 | 0.001 | 0.844 | GABA C receptor agonist | 0.484 0.004 DBMET00502 0.717 0.002 DBMET00494 | ||
| 0.819 | 0.003 | 0.919 | Superoxide dismutase inhibitor | 0.919 0.002 DBMET00502 0.5 0.013 DBMET00494 | DBMET00502 | |
| 0.807 | 0.001 | 0.807 | Glutamate dehydrogenase inhibitor | 0.442 0.004 DBMET00502 0.151 0.016 DBMET00494 | ||
| 0.797 | 0.001 | 0.858 | Ornithine carbamoyltransferase inhibitor | 0.858 0.001 DBMET00502 0.091 0.018 DBMET00494 | DBMET00502 | |
| 0.691 | 0.003 | 0.726 | Phospholipase C inhibitor | 0.726 0.003 DBMET00502 0.256 0.024 DBMET00494 | DBMET00502 | |
| 0.684 | 0.004 | 0.684 | Psychostimulant | 0.634 0.005 DBMET00502 0.527 0.009 DBMET00494 | ||
| 0.681 | 0.003 | 0.681 | Peroxidase inhibitor | 0.497 0.01 DBMET00502 0.191 0.062 DBMET00494 | ||
| 0.685 | 0.008 | 0.685 | 5 Hydroxytryptamine release stimulant | 0.37 0.052 DBMET00502 0.575 0.017 DBMET00494 | ||
| 0.647 | 0.004 | 0.787 | Interleukin agonist | 0.787 0.003 DBMET00502 0.426 0.015 DBMET00494 | DBMET00502 | |
| 0.639 | 0.002 | 0.639 | Histidine decarboxylase inhibitor | 0.628 0.002 DBMET00502 0.149 0.02 DBMET00494 | ||
| 0.625 | 0.002 | 0.625 | NMDA receptor agonist | 0.216 0.004 DBMET00502 0.376 0.003 DBMET00494 | ||
| 0.617 | 0.003 | 0.617 | Tyrosine 3 hydroxylase inhibitor | 0.393 0.009 DBMET00502 0.489 0.004 DBMET00494 | ||
| 0.613 | 0.01 | 0.613 | Immunomodulator | 0.501 0.023 DBMET00502 0.313 0.075 DBMET00494 | ||
| 0.591 | 0.004 | 0.628 | Interleukin 2 agonist | 0.628 0.003 DBMET00502 0.442 0.017 DBMET00494 | DBMET00502 | |
| 0.583 | 0.002 | 0.755 | Aminopeptidase B inhibitor | 0.755 0.002 DBMET00502 0.251 0.013 DBMET00494 | DBMET00502 | |
| 0.585 | 0.004 | 0.683 | Thrombolytic | 0.683 0.004 DBMET00502 0.318 0.021 DBMET00494 | DBMET00502 | |
| 0.581 | 0.002 | 0.581 | GABA aminotransferase inhibitor | 0.121 0.015 DBMET00502 0.103 0.025 DBMET00494 | ||
| 0.57 | 0.004 | 0.57 | Growth hormone agonist | 0.515 0.005 DBMET00502 | ||
| 0.564 | 0.004 | 0.564 | Hematopoietic | 0.431 0.004 DBMET00502 0.132 0.018 DBMET00494 | ||
| 0.573 | 0.013 | 0.573 | Histamine release inhibitor | 0.289 0.13 DBMET00502 0.383 0.084 DBMET00494 | ||
| 0.577 | 0.022 | 0.577 | Aldehyde oxidase inhibitor | 0.304 0.065 DBMET00502 0.356 0.054 DBMET00494 | ||
| 0.568 | 0.014 | 0.603 | Interleukin antagonist | 0.603 0.012 DBMET00502 | DBMET00502 | |
| 0.554 | 0.009 | 0.765 | Platelet antagonist | 0.765 0.004 DBMET00502 0.272 0.063 DBMET00494 | DBMET00502 | |
| 0.544 | 0.002 | 0.544 | Carbamoyl phosphate synthetase inhibitor | 0.3 0.004 DBMET00502 0.125 0.015 DBMET00494 | ||
| 0.549 | 0.009 | 0.625 | Angiogenesis stimulant | 0.625 0.006 DBMET00502 0.278 0.058 DBMET00494 | DBMET00502 | |
| 0.54 | 0.024 | 0.595 | Immunostimulant | 0.595 0.017 DBMET00502 0.359 0.062 DBMET00494 | DBMET00502 | |
| 0.52 | 0.005 | 0.627 | Alpha-N-acetylglucosaminidase inhibitor | 0.283 0.018 DBMET00502 0.627 0.004 DBMET00494 | DBMET00494 | |
| 0.517 | 0.004 | 0.517 | 5 Hydroxytryptamine uptake stimulant | 0.335 0.03 DBMET00502 0.401 0.014 DBMET00494 | ||
| 0.507 | 0.002 | 0.774 | Argininosuccinate synthase inhibitor | 0.774 0.001 DBMET00502 0.147 0.012 DBMET00494 | DBMET00502 | |
| 0.492 | 0.002 | 0.492 | Phenylalanine 4-hydroxylase inhibitor | 0.184 0.008 DBMET00502 0.132 0.015 DBMET00494 | ||
| 0.483 | 0.002 | 0.483 | AMPA 4 receptor antagonist | 0.182 0.003 DBMET00502 0.254 0.003 DBMET00494 | ||
| 0.508 | 0.028 | 0.682 | Antithrombotic | 0.682 0.009 DBMET00502 0.42 0.045 DBMET00494 | DBMET00502 | |
| 0.459 | 0.004 | 0.459 | Alcohol oxidase inhibitor | 0.053 0.041 DBMET00502 0.173 0.008 DBMET00494 | ||
| 0.458 | 0.012 | 0.788 | Anticoagulant | 0.788 0.004 DBMET00502 0.288 0.03 DBMET00494 | DBMET00502 | |
| 0.437 | 0.001 | 0.725 | Lysine carboxypeptidase inhibitor | 0.725 0 DBMET00502 0.104 0.004 DBMET00494 | DBMET00502 | |
| 0.439 | 0.003 | 0.439 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.217 0.013 DBMET00502 0.312 0.005 DBMET00494 | ||
| 0.428 | 0.005 | 0.428 | Peptidyltransferase inhibitor | 0.362 0.01 DBMET00502 0.192 0.11 DBMET00494 | ||
| 0.463 | 0.052 | 0.481 | Antibacterial | 0.481 0.046 DBMET00502 0.448 0.058 DBMET00494 | DBMET00502 | |
| 0.428 | 0.018 | 0.492 | Insulysin inhibitor | 0.492 0.01 DBMET00502 0.437 0.017 DBMET00494 | DBMET00502 | |
| 0.456 | 0.049 | 0.507 | 5 Hydroxytryptamine release inhibitor | 0.337 0.127 DBMET00502 0.507 0.03 DBMET00494 | DBMET00494 | |
| 0.41 | 0.003 | 0.41 | Adenylate kinase inhibitor | 0.309 0.006 DBMET00502 0.169 0.021 DBMET00494 | ||
| 0.407 | 0.003 | 0.676 | Nitric-oxide synthase inhibitor | 0.676 0.002 DBMET00502 0.17 0.016 DBMET00494 | DBMET00502 | |
| 0.406 | 0.003 | 0.406 | GABA C receptor antagonist | 0.135 0.039 DBMET00502 0.283 0.005 DBMET00494 | ||
| 0.406 | 0.003 | 0.473 | NMDA 2C receptor antagonist | 0.473 0.003 DBMET00502 0.314 0.004 DBMET00494 | DBMET00502 | |
| 0.401 | 0.003 | 0.691 | Inducible nitric-oxide synthase inhibitor | 0.691 0.002 DBMET00502 0.136 0.019 DBMET00494 | DBMET00502 | |
| 0.4 | 0.002 | 0.4 | Ornithine decarboxylase inhibitor | 0.329 0.003 DBMET00502 0.105 0.039 DBMET00494 | ||
| 0.399 | 0.004 | 0.399 | Catalase inhibitor | 0.236 0.01 DBMET00502 0.087 0.044 DBMET00494 | ||
| 0.391 | 0.003 | 0.601 | NMDA 2A receptor antagonist | 0.601 0.002 DBMET00502 0.226 0.004 DBMET00494 | DBMET00502 | |
| 0.385 | 0.003 | 0.385 | Glycine transporter 2 inhibitor | 0.273 0.004 DBMET00502 | ||
| 0.383 | 0.004 | 0.383 | Aminoacyl-tRNA synthetase inhibitor | 0.286 0.007 DBMET00502 | ||
| 0.413 | 0.035 | 0.427 | Apoptosis antagonist | 0.427 0.032 DBMET00502 | DBMET00502 | |
| 0.382 | 0.005 | 0.471 | NMDA receptor antagonist | 0.462 0.004 DBMET00502 0.471 0.004 DBMET00494 | DBMET00494 | |
| 0.371 | 0.002 | 0.371 | Glutamate (mGluR6) antagonist | 0.129 0.005 DBMET00502 0.193 0.003 DBMET00494 | ||
| 0.419 | 0.053 | 0.419 | GABA C receptor rho-3 antagonist | 0.214 0.191 DBMET00502 0.382 0.07 DBMET00494 | ||
| 0.385 | 0.024 | 0.385 | DNA synthesis inhibitor | 0.347 0.031 DBMET00502 0.373 0.026 DBMET00494 | ||
| 0.362 | 0.004 | 0.362 | Phosphofructokinase-1 inhibitor | 0.236 0.008 DBMET00502 0.138 0.02 DBMET00494 | ||
| 0.361 | 0.002 | 0.361 | AMPA 3 receptor antagonist | 0.075 0.005 DBMET00502 0.184 0.003 DBMET00494 | ||
| 0.35 | 0.003 | 0.35 | Kainate receptor antagonist | 0.15 0.005 DBMET00502 0.252 0.003 DBMET00494 | ||
| 0.353 | 0.009 | 0.442 | Insulin sensitizer | 0.442 0.005 DBMET00502 0.187 0.087 DBMET00494 | DBMET00502 | |
| 0.354 | 0.011 | 0.429 | Hemostatic | 0.429 0.006 DBMET00502 0.226 0.025 DBMET00494 | DBMET00502 | |
| 0.344 | 0.005 | 0.344 | Ferrochelatase inhibitor | 0.178 0.028 DBMET00502 0.307 0.007 DBMET00494 | ||
| 0.347 | 0.01 | 0.437 | Neurotensin receptor agonist | 0.437 0.006 DBMET00502 0.225 0.026 DBMET00494 | DBMET00502 | |
| 0.338 | 0.005 | 0.338 | Porphobilinogen synthase inhibitor | 0.067 0.059 DBMET00502 0.179 0.015 DBMET00494 | ||
| 0.368 | 0.036 | 0.368 | DNA damaging | 0.265 0.073 DBMET00502 | ||
| 0.334 | 0.005 | 0.334 | Histone deacetylase SIRT1 inhibitor | 0.282 0.01 DBMET00502 0.147 0.064 DBMET00494 | ||
| 0.331 | 0.002 | 0.331 | Glutamate (mGluR3) antagonist | 0.067 0.007 DBMET00502 0.143 0.004 DBMET00494 | ||
| 0.333 | 0.008 | 0.363 | Cell adhesion inhibitor | 0.363 0.006 DBMET00502 0.191 0.027 DBMET00494 | DBMET00502 | |
| 0.392 | 0.067 | 0.392 | Immunosuppressant | 0.351 0.086 DBMET00502 0.246 0.151 DBMET00494 | ||
| 0.37 | 0.046 | 0.41 | Vasodilator, coronary | 0.306 0.083 DBMET00502 0.41 0.032 DBMET00494 | DBMET00494 | |
| 0.334 | 0.011 | 0.334 | Alkylator | 0.272 0.014 DBMET00502 0.106 0.082 DBMET00494 | ||
| 0.341 | 0.018 | 0.356 | DNA methylase inhibitor | 0.235 0.057 DBMET00502 0.356 0.016 DBMET00494 | DBMET00494 | |
| 0.323 | 0.004 | 0.323 | Toll-Like receptor 2 antagonist | 0.196 0.025 DBMET00502 0.146 0.055 DBMET00494 | ||
| 0.314 | 0.002 | 0.314 | Glutamate (mGluR4) antagonist | 0.091 0.006 DBMET00502 0.215 0.003 DBMET00494 | ||
| 0.32 | 0.01 | 0.32 | Aldehyde dehydrogenase inhibitor | 0.147 0.049 DBMET00502 | ||
| 0.313 | 0.003 | 0.313 | AMPA 1 receptor antagonist | 0.305 0.003 DBMET00502 0.18 0.004 DBMET00494 | ||
| 0.324 | 0.015 | 0.337 | Bone formation stimulant | 0.337 0.014 DBMET00502 0.136 0.071 DBMET00494 | DBMET00502 | |
| 0.316 | 0.01 | 0.316 | Chelator | 0.132 0.044 DBMET00502 0.096 0.084 DBMET00494 | ||
| 0.315 | 0.009 | 0.327 | Cell wall synthesis inhibitor | 0.327 0.009 DBMET00502 0.325 0.009 DBMET00494 | DBMET00502 | |
| 0.306 | 0.003 | 0.306 | GABA C receptor rho-1 antagonist | 0.128 0.034 DBMET00502 0.256 0.004 DBMET00494 | ||
| 0.306 | 0.004 | 0.306 | Leukotriene A4 hydrolase inhibitor | 0.071 0.011 DBMET00502 0.177 0.004 DBMET00494 | ||
| 0.311 | 0.009 | 0.311 | Succinate dehydrogenase inhibitor | 0.206 0.044 DBMET00502 0.249 0.023 DBMET00494 | ||
| 0.372 | 0.07 | 0.372 | Transcription factor NF kappa B inhibitor | 0.277 0.108 DBMET00502 0.194 0.175 DBMET00494 | ||
| 0.304 | 0.005 | 0.516 | Integrin antagonist | 0.516 0.004 DBMET00502 0.258 0.005 DBMET00494 | DBMET00502 | |
| 0.359 | 0.061 | 0.359 | Cholesterol antagonist | 0.332 0.072 DBMET00494 | ||
| 0.316 | 0.02 | 0.514 | Diuretic | 0.514 0.007 DBMET00502 0.225 0.036 DBMET00494 | DBMET00502 | |
| 0.296 | 0.004 | 0.307 | Carbonic anhydrase stimulant | 0.307 0.004 DBMET00502 0.079 0.026 DBMET00494 | DBMET00502 | |
| 0.315 | 0.026 | 0.315 | Hepatoprotectant | 0.261 0.04 DBMET00502 0.178 0.082 DBMET00494 | ||
| 0.29 | 0.004 | 0.304 | Neurotensin receptor antagonist | 0.304 0.004 DBMET00502 0.04 0.037 DBMET00494 | DBMET00502 | |
| 0.294 | 0.014 | 0.294 | Adenylate cyclase inhibitor | 0.233 0.021 DBMET00502 0.117 0.07 DBMET00494 | ||
| 0.319 | 0.042 | 0.319 | Vasodilator | 0.221 0.088 DBMET00502 0.236 0.078 DBMET00494 | ||
| 0.33 | 0.059 | 0.423 | Spasmolytic | 0.271 0.082 DBMET00502 0.423 0.036 DBMET00494 | DBMET00494 | |
| 0.302 | 0.033 | 0.394 | Platelet adhesion inhibitor | 0.394 0.012 DBMET00502 0.247 0.05 DBMET00494 | DBMET00502 | |
| 0.301 | 0.032 | 0.319 | Gastrin inhibitor | 0.319 0.021 DBMET00502 0.319 0.022 DBMET00494 | DBMET00494 | |
| 0.271 | 0.002 | 0.271 | Kainate receptor 1 antagonist | 0.118 0.004 DBMET00502 0.213 0.003 DBMET00494 | ||
| 0.28 | 0.011 | 0.28 | Cystathionine beta-synthase inhibitor | 0.132 0.05 DBMET00502 0.104 0.072 DBMET00494 | ||
| 0.271 | 0.005 | 0.409 | NMDA 2 receptor antagonist | 0.409 0.004 DBMET00502 0.237 0.007 DBMET00494 | DBMET00502 | |
| 0.289 | 0.024 | 0.328 | Neuropeptide Y2 antagonist | 0.328 0.011 DBMET00502 0.179 0.162 DBMET00494 | DBMET00502 | |
| 0.277 | 0.012 | 0.574 | Glutamate receptor antagonist | 0.177 0.035 DBMET00502 0.574 0.004 DBMET00494 | DBMET00494 | |
| 0.292 | 0.029 | 0.359 | DNA methyltransferase I inhibitor | 0.2 0.069 DBMET00502 0.359 0.013 DBMET00494 | DBMET00494 | |
| 0.312 | 0.049 | 0.312 | Transcription factor STAT inhibitor | 0.187 0.158 DBMET00494 | ||
| 0.264 | 0.004 | 0.264 | Folate antagonist | 0.248 0.005 DBMET00502 0.091 0.085 DBMET00494 | ||
| 0.26 | 0.001 | 0.356 | Arginase inhibitor | 0.356 0.001 DBMET00502 0.154 0.002 DBMET00494 | DBMET00502 | |
| 0.291 | 0.035 | 0.291 | Anesthetic general | 0.285 0.037 DBMET00502 0.211 0.069 DBMET00494 | ||
| 0.259 | 0.004 | 0.259 | Adenylate cyclase stimulant | 0.216 0.008 DBMET00502 0.192 0.018 DBMET00494 | ||
| 0.257 | 0.004 | 0.257 | Aminopeptidase I inhibitor | 0.192 0.007 DBMET00502 0.175 0.009 DBMET00494 | ||
| 0.257 | 0.006 | 0.303 | Mucolytic | 0.303 0.004 DBMET00502 0.194 0.015 DBMET00494 | DBMET00502 | |
| 0.253 | 0.004 | 0.344 | NMDA receptor subunit 3B antagonist | 0.344 0.003 DBMET00502 0.306 0.004 DBMET00494 | DBMET00502 | |
| 0.25 | 0.004 | 0.25 | Kinesin antagonist | |||
| 0.25 | 0.004 | 0.25 | Kinesin-like protein 1 inhibitor | |||
| 0.255 | 0.012 | 0.285 | Expectorant | 0.285 0.009 DBMET00502 0.233 0.015 DBMET00494 | DBMET00502 | |
| 0.244 | 0.003 | 0.244 | Glycine receptor agonist | 0.07 0.054 DBMET00502 0.108 0.017 DBMET00494 | ||
| 0.248 | 0.008 | 0.248 | Alcohol dehydrogenase inhibitor | 0.092 0.061 DBMET00502 0.082 0.077 DBMET00494 | ||
| 0.246 | 0.009 | 0.246 | Cyclooxygenase 3 inhibitor | 0.127 0.069 DBMET00502 0.186 0.024 DBMET00494 | ||
| 0.244 | 0.007 | 0.244 | Triose-phosphate isomerase inhibitor | 0.118 0.033 DBMET00502 0.228 0.008 DBMET00494 | ||
| 0.25 | 0.014 | 0.402 | Cathepsin H inhibitor | 0.402 0.005 DBMET00502 0.142 0.053 DBMET00494 | DBMET00502 | |
| 0.322 | 0.086 | 0.459 | Vasodilator, peripheral | 0.423 0.048 DBMET00502 0.459 0.038 DBMET00494 | DBMET00494 | |
| 0.306 | 0.073 | 0.306 | Sodium/bile acid cotransporter inhibitor | 0.224 0.157 DBMET00494 | ||
| 0.237 | 0.005 | 0.619 | GP IIb/IIIa receptor antagonist | 0.619 0.003 DBMET00502 0.067 0.025 DBMET00494 | DBMET00502 | |
| 0.234 | 0.003 | 0.234 | Glutamate (mGluR group III) antagonist | 0.061 0.013 DBMET00502 0.171 0.003 DBMET00494 | ||
| 0.29 | 0.059 | 0.29 | Transcription factor STAT3 inhibitor | 0.183 0.159 DBMET00494 | ||
| 0.24 | 0.01 | 0.265 | Nav1.4 sodium channel blocker | 0.265 0.006 DBMET00502 | DBMET00502 | |
| 0.364 | 0.135 | 0.364 | Caspase 9 stimulant | 0.341 0.153 DBMET00494 | ||
| 0.287 | 0.057 | 0.364 | Hypoglycemic | 0.364 0.034 DBMET00502 0.165 0.155 DBMET00494 | DBMET00502 | |
| 0.231 | 0.003 | 0.231 | Fumarate hydratase inhibitor | 0.063 0.01 DBMET00502 0.051 0.013 DBMET00494 | ||
| 0.232 | 0.005 | 0.232 | Toll-Like receptor 2 agonist | 0.213 0.006 DBMET00502 0.038 0.031 DBMET00494 | ||
| 0.275 | 0.05 | 0.275 | Amyloid beta aggregation inhibitor | 0.145 0.111 DBMET00502 | ||
| 0.251 | 0.028 | 0.278 | Amylase inhibitor | 0.12 0.081 DBMET00502 0.278 0.022 DBMET00494 | DBMET00494 | |
| 0.234 | 0.011 | 0.234 | Histone deacetylase class III inhibitor | 0.192 0.022 DBMET00502 | ||
| 0.225 | 0.003 | 0.279 | AMPA 2 receptor antagonist | 0.097 0.005 DBMET00502 0.279 0.003 DBMET00494 | DBMET00494 | |
| 0.245 | 0.026 | 0.245 | Antipruritic | 0.138 0.109 DBMET00502 0.166 0.077 DBMET00494 | ||
| 0.223 | 0.004 | 0.223 | Glutathione S-transferase inhibitor | 0.196 0.005 DBMET00502 | ||
| 0.344 | 0.126 | 0.37 | Cyclophilin D inhibitor | 0.288 0.173 DBMET00502 0.37 0.109 DBMET00494 | DBMET00494 | |
| 0.222 | 0.004 | 0.353 | NMDA receptor subunit 3A antagonist | 0.316 0.003 DBMET00502 0.353 0.003 DBMET00494 | DBMET00494 | |
| 0.267 | 0.051 | 0.37 | Anticonvulsant | 0.37 0.026 DBMET00494 | DBMET00494 | |
| 0.224 | 0.008 | 0.224 | Vanilloid 1 agonist | 0.161 0.029 DBMET00502 0.112 0.108 DBMET00494 | ||
| 0.282 | 0.069 | 0.282 | Antioxidant | 0.216 0.104 DBMET00502 | ||
| 0.22 | 0.009 | 0.22 | NADH dehydrogenase inhibitor | 0.105 0.039 DBMET00502 0.156 0.016 DBMET00494 | ||
| 0.237 | 0.027 | 0.237 | Phospholipase A2 inhibitor | 0.149 0.075 DBMET00502 0.121 0.116 DBMET00494 | ||
| 0.239 | 0.029 | 0.287 | Thiol protease inhibitor | 0.287 0.021 DBMET00502 0.166 0.057 DBMET00494 | DBMET00502 | |
| 0.271 | 0.062 | 0.271 | Antiamyloidogenic | 0.15 0.148 DBMET00494 | ||
| 0.269 | 0.061 | 0.269 | Free radical scavenger | 0.235 0.075 DBMET00502 | ||
| 0.217 | 0.009 | 0.308 | CXC chemokine 4 receptor antagonist | 0.308 0.005 DBMET00502 0.169 0.013 DBMET00494 | DBMET00502 | |
| 0.211 | 0.005 | 0.211 | DOPA decarboxylase inhibitor | 0.125 0.04 DBMET00502 0.141 0.027 DBMET00494 | ||
| 0.208 | 0.01 | 0.208 | Glutamate receptor agonist | 0.192 0.011 DBMET00494 | ||
| 0.206 | 0.009 | 0.206 | Antimetabolite | 0.194 0.01 DBMET00502 0.051 0.031 DBMET00494 | ||
| 0.229 | 0.032 | 0.229 | Protein kinase stimulant | 0.192 0.044 DBMET00494 | ||
| 0.202 | 0.006 | 0.234 | Heat shock protein 70 antagonist | 0.234 0.004 DBMET00502 0.175 0.015 DBMET00494 | DBMET00502 | |
| 0.198 | 0.003 | 0.216 | Kainate receptor 2 antagonist | 0.079 0.007 DBMET00502 0.216 0.003 DBMET00494 | DBMET00494 | |
| 0.207 | 0.011 | 0.207 | Photosensitizer | |||
| 0.199 | 0.005 | 0.199 | Histamine N-methyltransferase inhibitor | 0.17 0.009 DBMET00502 0.096 0.049 DBMET00494 | ||
| 0.208 | 0.015 | 0.208 | Carbonic anhydrase III inhibitor | |||
| 0.199 | 0.007 | 0.199 | Somatostatin 1 agonist | 0.146 0.014 DBMET00502 0.166 0.01 DBMET00494 | ||
| 0.196 | 0.004 | 0.196 | Sirtuin 1 inhibitor | 0.125 0.013 DBMET00502 | ||
| 0.224 | 0.033 | 0.224 | Acetylcholine M1 receptor antagonist | 0.136 0.089 DBMET00502 0.217 0.035 DBMET00494 | ||
| 0.203 | 0.012 | 0.203 | Interleukin 8 antagonist | 0.183 0.018 DBMET00502 0.125 0.055 DBMET00494 | ||
| 0.191 | 0.002 | 0.191 | Kainate receptor agonist | 0.082 0.004 DBMET00502 0.126 0.002 DBMET00494 | ||
| 0.198 | 0.009 | 0.198 | Prolactin inhibitor | 0.093 0.063 DBMET00502 0.177 0.013 DBMET00494 | ||
| 0.191 | 0.004 | 0.191 | GABA B receptor agonist | 0.087 0.029 DBMET00502 0.098 0.018 DBMET00494 | ||
| 0.236 | 0.049 | 0.236 | Non-steroidal antiinflammatory agent | 0.222 0.056 DBMET00502 | ||
| 0.218 | 0.032 | 0.235 | Interleukin 6 antagonist | 0.235 0.026 DBMET00502 | DBMET00502 | |
| 0.19 | 0.005 | 0.19 | Glutamate (mGluR7) agonist | 0.125 0.026 DBMET00502 0.106 0.049 DBMET00494 | ||
| 0.186 | 0.001 | 0.186 | Glutamate (mGluR8) agonist | 0.091 0.003 DBMET00502 0.057 0.008 DBMET00494 | ||
| 0.186 | 0.002 | 0.186 | Glutamate (mGluR1a) agonist | 0.103 0.004 DBMET00502 0.069 0.004 DBMET00494 | ||
| 0.181 | 0.003 | 0.472 | Complement C3a chemotactic receptor antagonist | 0.472 0.002 DBMET00502 | DBMET00502 | |
| 0.183 | 0.007 | 0.183 | Interferon agonist | 0.152 0.01 DBMET00502 0.101 0.028 DBMET00494 | ||
| 0.177 | 0.003 | 0.197 | Glutamate (mGluR1) agonist | 0.063 0.004 DBMET00502 0.197 0.003 DBMET00494 | DBMET00494 | |
| 0.177 | 0.004 | 0.177 | Glutamate (mGluR group III) agonist | 0.054 0.021 DBMET00502 0.038 0.037 DBMET00494 | ||
| 0.21 | 0.038 | 0.21 | Interferon gamma antagonist | 0.189 0.045 DBMET00502 0.2 0.041 DBMET00494 | ||
| 0.225 | 0.054 | 0.225 | Nitric-oxide synthase stimulant | 0.171 0.149 DBMET00502 0.212 0.071 DBMET00494 | ||
| 0.175 | 0.005 | 0.175 | AMPA receptor antagonist | 0.083 0.016 DBMET00502 0.133 0.007 DBMET00494 | ||
| 0.173 | 0.003 | 0.462 | Endothelial nitric-oxide synthase inhibitor | 0.462 0.002 DBMET00502 0.035 0.017 DBMET00494 | DBMET00502 | |
| 0.176 | 0.009 | 0.256 | Factor V inhibitor | 0.256 0.003 DBMET00502 0.095 0.081 DBMET00494 | DBMET00502 | |
| 0.2 | 0.036 | 0.2 | Insulin secretagoues | 0.182 0.047 DBMET00502 0.153 0.072 DBMET00494 | ||
| 0.167 | 0.007 | 0.342 | Erythropoietin receptor agonist | 0.342 0.005 DBMET00502 | DBMET00502 | |
| 0.168 | 0.012 | 0.266 | Cell adhesion molecule inhibitor | 0.266 0.005 DBMET00502 0.106 0.031 DBMET00494 | DBMET00502 | |
| 0.179 | 0.024 | 0.239 | Sphingosine 1-phosphate receptor 5 antagonist | 0.239 0.004 DBMET00494 | DBMET00494 | |
| 0.173 | 0.019 | 0.173 | Sphingosine 1-phosphate receptor 2 antagonist | 0.128 0.078 DBMET00502 0.16 0.029 DBMET00494 | ||
| 0.161 | 0.007 | 0.161 | Sphingosine 1-phosphate receptor 4 agonist | 0.093 0.028 DBMET00502 | ||
| 0.171 | 0.017 | 0.171 | Creatine kinase inhibitor | 0.15 0.024 DBMET00494 | ||
| 0.155 | 0.001 | 0.155 | Glutamate (mGluR6) agonist | 0.027 0.003 DBMET00502 0.015 0.006 DBMET00494 | ||
| 0.173 | 0.02 | 0.173 | Opioid antagonist | 0.144 0.028 DBMET00502 0.115 0.039 DBMET00494 | ||
| 0.169 | 0.016 | 0.169 | Opioid delta receptor antagonist | 0.144 0.021 DBMET00502 0.088 0.033 DBMET00494 | ||
| 0.154 | 0.004 | 0.162 | NMDA receptor glycine site agonist | 0.074 0.033 DBMET00502 0.162 0.004 DBMET00494 | DBMET00494 | |
| 0.154 | 0.009 | 0.154 | Acyl-CoA dehydrogenase inhibitor | 0.084 0.021 DBMET00502 0.097 0.017 DBMET00494 | ||
| 0.149 | 0.005 | 0.193 | Angiotensin-converting enzyme inhibitor | 0.087 0.011 DBMET00502 0.193 0.004 DBMET00494 | DBMET00494 | |
| 0.15 | 0.009 | 0.15 | Biliverdin reductase inhibitor | 0.138 0.011 DBMET00494 | ||
| 0.166 | 0.026 | 0.166 | Carbonic anhydrase XV inhibitor | 0.105 0.061 DBMET00494 | ||
| 0.159 | 0.02 | 0.276 | Cathepsin G inhibitor | 0.276 0.011 DBMET00502 0.086 0.039 DBMET00494 | DBMET00502 | |
| 0.206 | 0.067 | 0.206 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.161 0.124 DBMET00494 | ||
| 0.14 | 0.002 | 0.225 | Carboxypeptidase B inhibitor | 0.225 0.002 DBMET00502 0.034 0.021 DBMET00494 | DBMET00502 | |
| 0.153 | 0.017 | 0.155 | Selectin antagonist | 0.155 0.017 DBMET00502 | DBMET00502 | |
| 0.215 | 0.08 | 0.27 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.27 0.051 DBMET00502 | DBMET00502 | |
| 0.15 | 0.017 | 0.15 | Interleukin 1 beta converting enzyme inhibitor | 0.095 0.065 DBMET00502 | ||
| 0.138 | 0.005 | 0.138 | Aconitate hydratase inhibitor | 0.058 0.028 DBMET00502 0.097 0.009 DBMET00494 | ||
| 0.264 | 0.131 | 0.347 | Calcium channel activator | 0.347 0.052 DBMET00494 | DBMET00494 | |
| 0.136 | 0.003 | 0.136 | Kainate receptor 3 antagonist | 0.032 0.005 DBMET00502 0.136 0.003 DBMET00494 | ||
| 0.147 | 0.017 | 0.147 | Protein kinase B gamma inhibitor | |||
| 0.145 | 0.014 | 0.265 | Factor XII inhibitor | 0.265 0.004 DBMET00502 0.077 0.073 DBMET00494 | DBMET00502 | |
| 0.157 | 0.028 | 0.17 | Ca2+-transporting ATPase inhibitor | 0.17 0.013 DBMET00494 | DBMET00494 | |
| 0.132 | 0.004 | 0.236 | Kainate receptor 5 antagonist | 0.034 0.008 DBMET00502 0.236 0.003 DBMET00494 | DBMET00494 | |
| 0.18 | 0.052 | 0.18 | Melanin inhibitor | 0.174 0.056 DBMET00502 0.161 0.068 DBMET00494 | ||
| 0.139 | 0.011 | 0.157 | Glucagon-like peptide 1 agonist | 0.157 0.007 DBMET00502 | DBMET00502 | |
| 0.147 | 0.019 | 0.147 | Anabolic | 0.142 0.022 DBMET00502 0.104 0.058 DBMET00494 | ||
| 0.138 | 0.01 | 0.138 | Aminopeptidase microsomal inhibitor | 0.121 0.013 DBMET00502 | ||
| 0.221 | 0.094 | 0.228 | Calpain inhibitor | 0.228 0.087 DBMET00502 | DBMET00502 | |
| 0.145 | 0.018 | 0.145 | Opioid mu receptor antagonist | 0.117 0.026 DBMET00502 0.081 0.039 DBMET00494 | ||
| 0.128 | 0.004 | 0.17 | Mannosidase inhibitor | 0.17 0.004 DBMET00502 0.168 0.004 DBMET00494 | DBMET00502 | |
| 0.127 | 0.005 | 0.127 | Somatostatin 2 antagonist | 0.047 0.016 DBMET00502 | ||
| 0.166 | 0.044 | 0.259 | Neuropeptide Y1 antagonist | 0.259 0.007 DBMET00502 0.155 0.057 DBMET00494 | DBMET00502 | |
| 0.135 | 0.016 | 0.135 | Glutamate (mGluR) agonist | |||
| 0.124 | 0.004 | 0.167 | Alpha-mannosidase inhibitor | 0.098 0.007 DBMET00502 0.167 0.004 DBMET00494 | DBMET00494 | |
| 0.133 | 0.015 | 0.133 | Myeloperoxidase inhibitor | 0.107 0.028 DBMET00502 | ||
| 0.122 | 0.004 | 0.122 | Glutamate (mGluR7) antagonist | 0.068 0.047 DBMET00502 0.11 0.007 DBMET00494 | ||
| 0.134 | 0.018 | 0.237 | Neuropeptide agonist | 0.237 0.004 DBMET00502 | DBMET00502 | |
| 0.13 | 0.016 | 0.142 | Glutamate release inhibitor | 0.142 0.012 DBMET00502 0.105 0.036 DBMET00494 | DBMET00502 | |
| 0.119 | 0.005 | 0.121 | VLA-4 antagonist | 0.121 0.005 DBMET00502 0.058 0.011 DBMET00494 | DBMET00502 | |
| 0.119 | 0.005 | 0.119 | Integrin alpha4 antagonist | 0.08 0.008 DBMET00502 0.052 0.011 DBMET00494 | ||
| 0.121 | 0.007 | 0.121 | Interferon inducer | 0.089 0.018 DBMET00502 0.069 0.036 DBMET00494 | ||
| 0.115 | 0.002 | 0.119 | Glutamate (mGluR8) antagonist | 0.074 0.004 DBMET00502 0.119 0.002 DBMET00494 | DBMET00494 | |
| 0.149 | 0.037 | 0.244 | Falcipain 3 inhibitor | 0.244 0.008 DBMET00502 0.129 0.048 DBMET00494 | DBMET00502 | |
| 0.116 | 0.004 | 0.116 | Somatostatin 5 agonist | 0.045 0.015 DBMET00502 | ||
| 0.118 | 0.007 | 0.187 | Botulinum neurotoxin type A inhibitor | 0.187 0.004 DBMET00502 | DBMET00502 | |
| 0.145 | 0.036 | 0.145 | DNA repair enzyme inhibitor | |||
| 0.112 | 0.003 | 0.112 | Calcium-sensing receptor agonist | 0.072 0.004 DBMET00502 | ||
| 0.119 | 0.011 | 0.119 | Glutamate (mGluR1) antagonist | 0.1 0.016 DBMET00494 | ||
| 0.117 | 0.01 | 0.117 | Aminopeptidase N inhibitor | 0.098 0.013 DBMET00502 | ||
| 0.111 | 0.003 | 0.111 | Membrane dipeptidase inhibitor | 0.089 0.004 DBMET00502 0.072 0.007 DBMET00494 | ||
| 0.123 | 0.016 | 0.123 | Ribonucleotide reductase inhibitor | 0.067 0.032 DBMET00502 | ||
| 0.137 | 0.031 | 0.137 | HIV-1 integrase (Overall Integration) inhibitor | 0.1 0.054 DBMET00502 0.124 0.037 DBMET00494 | ||
| 0.14 | 0.036 | 0.14 | Caspase 3 inhibitor | 0.127 0.05 DBMET00494 | ||
| 0.121 | 0.018 | 0.358 | Thrombin inhibitor | 0.358 0.004 DBMET00502 0.08 0.041 DBMET00494 | DBMET00502 | |
| 0.108 | 0.006 | 0.108 | Somatostatin 1 antagonist | 0.054 0.018 DBMET00502 0.046 0.022 DBMET00494 | ||
| 0.106 | 0.004 | 0.106 | Dipeptidyl peptidase II inhibitor | 0.095 0.004 DBMET00502 0.047 0.01 DBMET00494 | ||
| 0.188 | 0.086 | 0.198 | 5 Hydroxytryptamine 3E antagonist | 0.198 0.066 DBMET00494 | DBMET00494 | |
| 0.13 | 0.029 | 0.178 | Electrolyte absorption antagonist | 0.178 0.012 DBMET00494 | DBMET00494 | |
| 0.108 | 0.007 | 0.12 | Somatostatin agonist | 0.034 0.02 DBMET00502 0.12 0.007 DBMET00494 | DBMET00494 | |
| 0.136 | 0.036 | 0.136 | Transcription factor STAT6 inhibitor | 0.132 0.041 DBMET00494 | ||
| 0.135 | 0.036 | 0.135 | Mediator release inhibitor | 0.097 0.073 DBMET00502 | ||
| 0.103 | 0.004 | 0.103 | Carbonic anhydrase I stimulant | 0.089 0.005 DBMET00502 | ||
| 0.102 | 0.006 | 0.102 | Somatostatin 5 antagonist | 0.027 0.025 DBMET00502 0.041 0.018 DBMET00494 | ||
| 0.166 | 0.07 | 0.166 | Arachidonic acid antagonist | 0.155 0.083 DBMET00494 | ||
| 0.1 | 0.005 | 0.1 | Carbonic anhydrase II stimulant | 0.087 0.007 DBMET00502 | ||
| 0.111 | 0.017 | 0.111 | Ribonucleoside-diphosphate reductase inhibitor | 0.063 0.032 DBMET00502 | ||
| 0.101 | 0.007 | 0.101 | Growth hormone release inhibitor | 0.044 0.027 DBMET00502 | ||
| 0.123 | 0.028 | 0.123 | Carbonic anhydrase VI inhibitor | |||
| 0.133 | 0.039 | 0.151 | Protease inhibitor | 0.151 0.029 DBMET00502 | DBMET00502 | |
| 0.098 | 0.004 | 0.098 | Glutamate (mGluR4) agonist | 0.032 0.027 DBMET00502 | ||
| 0.139 | 0.045 | 0.188 | Sphingosine 1-phosphate receptor 4 antagonist | 0.188 0.012 DBMET00494 | DBMET00494 | |
| 0.096 | 0.002 | 0.096 | Glutamate (mGluR3) agonist | 0.049 0.005 DBMET00502 0.074 0.003 DBMET00494 | ||
| 0.098 | 0.006 | 0.098 | Factor XIIIa inhibitor | 0.034 0.03 DBMET00502 | ||
| 0.144 | 0.052 | 0.164 | Anesthetic local | 0.093 0.09 DBMET00502 0.164 0.043 DBMET00494 | DBMET00494 | |
| 0.104 | 0.013 | 0.127 | Opioid mu receptor agonist | 0.127 0.009 DBMET00502 0.041 0.039 DBMET00494 | DBMET00502 | |
| 0.149 | 0.06 | 0.327 | Neurotrophic factor | 0.116 0.102 DBMET00502 0.327 0.007 DBMET00494 | DBMET00494 | |
| 0.155 | 0.067 | 0.21 | GABA C receptor rho-2 antagonist | 0.21 0.024 DBMET00494 | DBMET00494 | |
| 0.093 | 0.005 | 0.093 | Thymidylate synthase inhibitor | 0.075 0.009 DBMET00502 | ||
| 0.101 | 0.013 | 0.133 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.133 0.004 DBMET00502 0.087 0.026 DBMET00494 | DBMET00502 | |
| 0.103 | 0.016 | 0.285 | Trypsin inhibitor | 0.285 0.004 DBMET00502 0.067 0.036 DBMET00494 | DBMET00502 | |
| 0.139 | 0.053 | 0.158 | Proteasome inhibitor | 0.158 0.042 DBMET00502 | DBMET00502 | |
| 0.182 | 0.096 | 0.478 | Platelet aggregation inhibitor | 0.478 0.011 DBMET00502 | DBMET00502 | |
| 0.109 | 0.025 | 0.109 | Vanilloid agonist | 0.108 0.026 DBMET00502 | ||
| 0.096 | 0.011 | 0.096 | Nitric oxide donor | 0.087 0.016 DBMET00502 | ||
| 0.087 | 0.004 | 0.132 | Kainate receptor 4 antagonist | 0.036 0.011 DBMET00502 0.132 0.003 DBMET00494 | DBMET00494 | |
| 0.086 | 0.005 | 0.086 | Sirtuin 2 inhibitor | |||
| 0.092 | 0.01 | 0.122 | Calcitonin receptor agonist | 0.122 0.006 DBMET00502 0.048 0.017 DBMET00494 | DBMET00502 | |
| 0.106 | 0.026 | 0.106 | Na+ K+ transporting ATPase inhibitor | 0.074 0.056 DBMET00502 0.078 0.052 DBMET00494 | ||
| 0.106 | 0.027 | 0.106 | Keratolytic | 0.085 0.043 DBMET00494 | ||
| 0.084 | 0.006 | 0.245 | Integrin alpha5beta1 antagonist | 0.245 0.004 DBMET00502 0.095 0.005 DBMET00494 | DBMET00502 | |
| 0.111 | 0.033 | 0.111 | Metalloproteinase-2 inhibitor | 0.078 0.055 DBMET00502 0.093 0.042 DBMET00494 | ||
| 0.082 | 0.005 | 0.297 | Vitronectin receptor antagonist | 0.297 0.003 DBMET00502 | DBMET00502 | |
| 0.084 | 0.007 | 0.084 | AICAR transformylase inhibitor | 0.055 0.017 DBMET00502 0.047 0.025 DBMET00494 | ||
| 0.092 | 0.015 | 0.092 | Opioid agonist | 0.09 0.015 DBMET00502 0.047 0.044 DBMET00494 | ||
| 0.095 | 0.019 | 0.258 | Plasmin inhibitor | 0.258 0.005 DBMET00502 0.054 0.03 DBMET00494 | DBMET00502 | |
| 0.104 | 0.029 | 0.125 | Glycine receptor antagonist | 0.125 0.016 DBMET00494 | DBMET00494 | |
| 0.113 | 0.038 | 0.113 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.09 | 0.015 | 0.171 | Bombesin 2 receptor antagonist | 0.171 0.009 DBMET00502 0.055 0.028 DBMET00494 | DBMET00502 | |
| 0.138 | 0.065 | 0.403 | Nav1.2 sodium channel blocker | 0.403 0.007 DBMET00502 | DBMET00502 | |
| 0.077 | 0.004 | 0.18 | Integrin alphaVbeta3 antagonist | 0.18 0.003 DBMET00502 0.029 0.009 DBMET00494 | DBMET00502 | |
| 0.106 | 0.033 | 0.106 | Transcription factor NF kappa B stimulant | |||
| 0.081 | 0.009 | 0.081 | Adenine nucleotide translocase inhibitor | 0.057 0.035 DBMET00502 0.073 0.013 DBMET00494 | ||
| 0.081 | 0.009 | 0.081 | Adenosine deaminase inhibitor | 0.065 0.017 DBMET00502 0.054 0.026 DBMET00494 | ||
| 0.077 | 0.005 | 0.077 | Geranyltranstransferase inhibitor | 0.045 0.029 DBMET00502 0.059 0.015 DBMET00494 | ||
| 0.078 | 0.006 | 0.078 | Neurokinin 2 agonist | 0.04 0.03 DBMET00502 | ||
| 0.082 | 0.012 | 0.179 | Epithelial sodium channel blocker | 0.179 0.003 DBMET00502 | DBMET00502 | |
| 0.079 | 0.01 | 0.079 | Lysophosphatidic acid 3 receptor antagonist | 0.047 0.041 DBMET00502 0.046 0.043 DBMET00494 | ||
| 0.088 | 0.019 | 0.088 | Caspase 9 inhibitor | |||
| 0.117 | 0.048 | 0.117 | Urease inhibitor | |||
| 0.158 | 0.089 | 0.158 | Death-associated protein kinase 2 inhibitor | |||
| 0.074 | 0.006 | 0.074 | Somatostatin 4 antagonist | |||
| 0.099 | 0.031 | 0.138 | Analgesic, opioid | 0.138 0.017 DBMET00502 0.097 0.033 DBMET00494 | DBMET00502 | |
| 0.075 | 0.007 | 0.075 | GABA B receptor antagonist | 0.064 0.01 DBMET00494 | ||
| 0.077 | 0.01 | 0.077 | Glucose-6-phosphate isomerase inhibitor | 0.059 0.019 DBMET00494 | ||
| 0.088 | 0.021 | 0.17 | Plasminogen activator inhibitor | 0.17 0.005 DBMET00502 0.083 0.024 DBMET00494 | DBMET00502 | |
| 0.141 | 0.075 | 0.141 | Lipid peroxidase inhibitor | 0.116 0.098 DBMET00502 0.123 0.09 DBMET00494 | ||
| 0.1 | 0.034 | 0.1 | Granulocyte macrophage colony stimulating factor agonist | 0.099 0.037 DBMET00494 | ||
| 0.079 | 0.014 | 0.079 | Dipeptidyl peptidase inhibitor | 0.06 0.026 DBMET00502 0.077 0.015 DBMET00494 | ||
| 0.07 | 0.004 | 0.07 | AMPA receptor agonist | 0.039 0.019 DBMET00502 0.052 0.008 DBMET00494 | ||
| 0.156 | 0.092 | 0.165 | Catenin beta inhibitor | 0.144 0.121 DBMET00502 0.165 0.074 DBMET00494 | DBMET00494 | |
| 0.068 | 0.005 | 0.068 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.056 0.009 DBMET00502 0.051 0.014 DBMET00494 | ||
| 0.068 | 0.005 | 0.441 | Integrin beta3 antagonist | 0.441 0.003 DBMET00502 0.025 0.011 DBMET00494 | DBMET00502 | |
| 0.067 | 0.004 | 0.067 | Urotensin II agonist | |||
| 0.066 | 0.004 | 0.101 | Tryptophan 5 hydroxylase inhibitor | 0.066 0.004 DBMET00502 0.101 0.002 DBMET00494 | DBMET00494 | |
| 0.087 | 0.025 | 0.088 | Phospholipase D inhibitor | 0.088 0.024 DBMET00494 | DBMET00494 | |
| 0.08 | 0.018 | 0.08 | Endothelin-converting enzyme inhibitor | 0.044 0.035 DBMET00502 | ||
| 0.124 | 0.063 | 0.124 | Beta amyloid protein antagonist | |||
| 0.069 | 0.009 | 0.069 | GHS receptor agonist | 0.041 0.033 DBMET00502 | ||
| 0.116 | 0.056 | 0.132 | Protein kinase C gamma inhibitor | 0.093 0.091 DBMET00502 0.132 0.044 DBMET00494 | DBMET00494 | |
| 0.087 | 0.028 | 0.095 | Neutrophil collagenase inhibitor | 0.095 0.024 DBMET00494 | DBMET00494 | |
| 0.12 | 0.06 | 0.152 | Microtubule formation inhibitor | 0.152 0.036 DBMET00494 | DBMET00494 | |
| 0.073 | 0.014 | 0.073 | Macrophage elastase inhibitor | |||
| 0.064 | 0.005 | 0.151 | Bradykinin B2 receptor agonist | 0.151 0.003 DBMET00502 | DBMET00502 | |
| 0.122 | 0.065 | 0.138 | Acetylcholine muscarinic antagonist | 0.138 0.052 DBMET00494 | DBMET00494 | |
| 0.077 | 0.02 | 0.179 | Protease activated receptor 1 antagonist | 0.179 0.004 DBMET00502 | DBMET00502 | |
| 0.102 | 0.045 | 0.102 | Bile acid receptor antagonist | 0.092 0.067 DBMET00494 | ||
| 0.091 | 0.036 | 0.091 | Histone deacetylase SIRT2 inhibitor | 0.079 0.046 DBMET00502 | ||
| 0.086 | 0.031 | 0.112 | MAP kinase kinase 7 inhibitor | 0.112 0.006 DBMET00494 | DBMET00494 | |
| 0.06 | 0.005 | 0.06 | Integrin beta7 antagonist | 0.03 0.009 DBMET00502 | ||
| 0.065 | 0.01 | 0.071 | Dopamine D5 agonist | 0.071 0.008 DBMET00494 | DBMET00494 | |
| 0.183 | 0.128 | 0.22 | RNA-directed DNA polymerase inhibitor | 0.22 0.073 DBMET00494 | DBMET00494 | |
| 0.066 | 0.012 | 0.071 | Oxytocin agonist | 0.071 0.009 DBMET00502 0.058 0.018 DBMET00494 | DBMET00502 | |
| 0.063 | 0.01 | 0.116 | Neuraminidase (Influenza A) inhibitor | 0.116 0.004 DBMET00502 0.077 0.005 DBMET00494 | DBMET00502 | |
| 0.062 | 0.009 | 0.062 | Dihydrofolate reductase inhibitor | 0.046 0.025 DBMET00502 | ||
| 0.104 | 0.052 | 0.126 | Potassium channel (Ca-activated) activator | 0.126 0.038 DBMET00494 | DBMET00494 | |
| 0.074 | 0.023 | 0.08 | Histone deacetylase SIRT3 inhibitor | 0.08 0.018 DBMET00502 0.06 0.05 DBMET00494 | DBMET00502 | |
| 0.098 | 0.047 | 0.098 | Protein kinase A inhibitor | |||
| 0.067 | 0.017 | 0.248 | CD45 antagonist | 0.248 0.004 DBMET00502 0.063 0.019 DBMET00494 | DBMET00502 | |
| 0.061 | 0.011 | 0.061 | Parathyroid hormone antagonist | |||
| 0.093 | 0.043 | 0.093 | Opioid kappa receptor antagonist | 0.086 0.05 DBMET00502 0.089 0.047 DBMET00494 | ||
| 0.058 | 0.008 | 0.182 | Integrin alpha2 antagonist | 0.038 0.023 DBMET00502 0.182 0.002 DBMET00494 | DBMET00494 | |
| 0.055 | 0.005 | 0.055 | Integrin alpha4beta7 antagonist | 0.052 0.005 DBMET00502 | ||
| 0.083 | 0.035 | 0.083 | Vanilloid 4 agonist | 0.081 0.038 DBMET00494 | ||
| 0.077 | 0.03 | 0.077 | Protease 3C (Human rhinovirus) inhibitor | 0.067 0.04 DBMET00494 | ||
| 0.111 | 0.064 | 0.186 | 5 Hydroxytryptamine 3A agonist | 0.186 0.02 DBMET00502 0.096 0.08 DBMET00494 | DBMET00502 | |
| 0.058 | 0.011 | 0.082 | GABA uptake inhibitor | 0.082 0.005 DBMET00494 | DBMET00494 | |
| 0.054 | 0.007 | 0.054 | VCAM-1 antagonist | 0.044 0.015 DBMET00502 | ||
| 0.082 | 0.036 | 0.082 | Matrix metalloproteinase inhibitor | 0.078 0.038 DBMET00494 | ||
| 0.099 | 0.052 | 0.099 | Protein kinase C zeta inhibitor | 0.095 0.058 DBMET00502 0.09 0.065 DBMET00494 | ||
| 0.053 | 0.007 | 0.053 | VCAM antagonist | 0.044 0.015 DBMET00502 | ||
| 0.048 | 0.003 | 0.089 | Carboxypeptidase B2 inhibitor | 0.089 0.002 DBMET00502 | DBMET00502 | |
| 0.054 | 0.009 | 0.054 | Peptide deformylase inhibitor | 0.029 0.022 DBMET00494 | ||
| 0.057 | 0.012 | 0.057 | Phosphoglycerate kinase inhibitor | 0.032 0.028 DBMET00502 | ||
| 0.048 | 0.003 | 0.048 | Carbonic anhydrase VIII inhibitor | 0.016 0.013 DBMET00494 | ||
| 0.048 | 0.003 | 0.048 | Carbonic anhydrase X inhibitor | 0.016 0.013 DBMET00494 | ||
| 0.07 | 0.025 | 0.07 | Sphingosine 1-phosphate receptor 3 antagonist | 0.066 0.03 DBMET00494 | ||
| 0.058 | 0.014 | 0.058 | Sphingosine 1-phosphate receptor 1 agonist | 0.046 0.024 DBMET00494 | ||
| 0.122 | 0.078 | 0.154 | Antibacterial (Helicobacter pylori) | 0.154 0.043 DBMET00502 | DBMET00502 | |
| 0.057 | 0.013 | 0.059 | Dihydropteroate synthase inhibitor | 0.059 0.012 DBMET00502 | DBMET00502 | |
| 0.047 | 0.004 | 0.047 | Aminopeptidase A inhibitor | 0.022 0.009 DBMET00502 0.022 0.01 DBMET00494 | ||
| 0.056 | 0.013 | 0.056 | Cholecystokinin B agonist | 0.044 0.02 DBMET00502 | ||
| 0.282 | 0.239 | 0.475 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.475 0.046 DBMET00494 | DBMET00494 | |
| 0.046 | 0.003 | 0.052 | Vanilloid 2 agonist | 0.052 0.003 DBMET00502 0.024 0.022 DBMET00494 | DBMET00502 | |
| 0.068 | 0.026 | 0.068 | Matrix metalloproteinase (membrane-type) inhibitor | 0.065 0.028 DBMET00494 | ||
| 0.118 | 0.076 | 0.216 | Cholinergic antagonist | 0.216 0.028 DBMET00494 | DBMET00494 | |
| 0.072 | 0.031 | 0.072 | Protein kinase C iota inhibitor | |||
| 0.064 | 0.023 | 0.064 | Phosphorylase inhibitor | |||
| 0.056 | 0.015 | 0.064 | Dipeptidyl peptidase IV inhibitor | 0.043 0.035 DBMET00502 0.064 0.011 DBMET00494 | DBMET00494 | |
| 0.049 | 0.008 | 0.052 | Integrin alpha1beta1 antagonist | 0.038 0.028 DBMET00502 0.052 0.006 DBMET00494 | DBMET00494 | |
| 0.083 | 0.042 | 0.083 | Metalloproteinase-9 inhibitor | 0.067 0.062 DBMET00502 0.075 0.048 DBMET00494 | ||
| 0.052 | 0.011 | 0.25 | Tryptase inhibitor | 0.25 0.004 DBMET00502 0.045 0.016 DBMET00494 | DBMET00502 | |
| 0.044 | 0.004 | 0.044 | N-Acetylated alpha-linked acidic dipeptidase inhibitor | 0.018 0.008 DBMET00502 | ||
| 0.087 | 0.047 | 0.087 | Estrogen-related receptor beta agonist | |||
| 0.069 | 0.029 | 0.069 | Human rhinovirus A protease inhibitor | |||
| 0.103 | 0.064 | 0.103 | Toll-Like receptor 4 antagonist | |||
| 0.066 | 0.027 | 0.066 | Cyclin A1 inhibitor | 0.057 0.044 DBMET00502 | ||
| 0.108 | 0.07 | 0.108 | Monophenol monooxygenase inhibitor | |||
| 0.066 | 0.028 | 0.066 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.053 0.043 DBMET00494 | ||
| 0.056 | 0.018 | 0.065 | Cytokine production stimulant | 0.065 0.009 DBMET00502 | DBMET00502 | |
| 0.063 | 0.025 | 0.064 | Sphingosine 1-phosphate receptor 1 antagonist | 0.064 0.024 DBMET00494 | DBMET00494 | |
| 0.047 | 0.01 | 0.092 | Thrombin receptor antagonist | 0.092 0.004 DBMET00502 | DBMET00502 | |
| 0.042 | 0.005 | 0.042 | Purinergic P2Y15 antagonist | |||
| 0.099 | 0.062 | 0.19 | UDP-glucose 4-epimerase inhibitor | 0.19 0.019 DBMET00494 | DBMET00494 | |
| 0.05 | 0.013 | 0.05 | Prostacyclin antagonist | 0.029 0.027 DBMET00502 | ||
| 0.113 | 0.077 | 0.212 | Acetylcholine antagonist | 0.212 0.028 DBMET00494 | DBMET00494 | |
| 0.068 | 0.032 | 0.076 | Corticotropin releasing factor 2 receptor antagonist | 0.076 0.02 DBMET00502 | DBMET00502 | |
| 0.041 | 0.005 | 0.137 | Integrin alpha2beta1 antagonist | 0.026 0.019 DBMET00502 0.137 0.003 DBMET00494 | DBMET00494 | |
| 0.056 | 0.021 | 0.056 | Carbonic anhydrase IV inhibitor | |||
| 0.055 | 0.02 | 0.055 | Sphingosine 1-phosphate receptor agonist | 0.052 0.023 DBMET00494 | ||
| 0.098 | 0.062 | 0.112 | Sphingomyelinase inhibitor | 0.112 0.047 DBMET00494 | DBMET00494 | |
| 0.047 | 0.013 | 0.047 | Caspase 2 inhibitor | |||
| 0.057 | 0.023 | 0.152 | Melanocortin antagonist | 0.152 0.008 DBMET00502 0.059 0.021 DBMET00494 | DBMET00502 | |
| 0.048 | 0.014 | 0.052 | Opioid delta receptor agonist | 0.052 0.012 DBMET00502 | DBMET00502 | |
| 0.042 | 0.008 | 0.042 | Somatostatin 3 antagonist | |||
| 0.075 | 0.041 | 0.075 | Carbonic anhydrase VA inhibitor | |||
| 0.053 | 0.019 | 0.11 | Histamine H2 receptor agonist | 0.11 0.003 DBMET00502 | DBMET00502 | |
| 0.07 | 0.037 | 0.07 | MDM2 inhibitor | 0.069 0.042 DBMET00494 | ||
| 0.059 | 0.026 | 0.059 | Sphingosine 1-phosphate receptor 5 agonist | |||
| 0.046 | 0.014 | 0.16 | Trypsin I inhibitor | 0.16 0.005 DBMET00502 0.031 0.024 DBMET00494 | DBMET00502 | |
| 0.041 | 0.009 | 0.041 | Growth hormone releasing factor antagonist | |||
| 0.05 | 0.019 | 0.068 | Histamine H1 receptor agonist | 0.068 0.005 DBMET00502 | DBMET00502 | |
| 0.048 | 0.017 | 0.051 | Glutamate (mGluR group II) antagonist | 0.051 0.015 DBMET00494 | DBMET00494 | |
| 0.086 | 0.055 | 0.086 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | |||
| 0.064 | 0.033 | 0.112 | Sphingosine kinase inhibitor | 0.078 0.018 DBMET00502 0.112 0.005 DBMET00494 | DBMET00494 | |
| 0.035 | 0.005 | 0.078 | Integrin alphaVbeta1 antagonist | 0.078 0.004 DBMET00502 0.024 0.009 DBMET00494 | DBMET00502 | |
| 0.065 | 0.035 | 0.087 | Prolactin release inhibitor | 0.087 0.008 DBMET00494 | DBMET00494 | |
| 0.033 | 0.003 | 0.04 | CXC chemokine 4 receptor agonist | 0.04 0.002 DBMET00502 | DBMET00502 | |
| 0.082 | 0.052 | 0.101 | Chymotrypsin inhibitor | 0.101 0.036 DBMET00502 | DBMET00502 | |
| 0.063 | 0.033 | 0.218 | Maillard reaction inhibitor | 0.218 0.004 DBMET00502 | DBMET00502 | |
| 0.045 | 0.015 | 0.045 | Growth hormone releasing factor agonist | |||
| 0.038 | 0.009 | 0.043 | LFA antagonist | 0.034 0.011 DBMET00502 0.043 0.007 DBMET00494 | DBMET00494 | |
| 0.052 | 0.022 | 0.134 | Melanocortin 4 antagonist | 0.134 0.007 DBMET00502 0.061 0.018 DBMET00494 | DBMET00502 | |
| 0.056 | 0.027 | 0.059 | Metalloproteinase-3 inhibitor | 0.059 0.025 DBMET00502 0.055 0.028 DBMET00494 | DBMET00502 | |
| 0.045 | 0.016 | 0.045 | Antibiotic Aminoglycoside-like | 0.035 0.026 DBMET00502 | ||
| 0.09 | 0.061 | 0.09 | Thioredoxin inhibitor | |||
| 0.055 | 0.026 | 0.063 | HCV NS3/NS4A protease inhibitor | 0.063 0.019 DBMET00494 | DBMET00494 | |
| 0.032 | 0.003 | 0.072 | Tryptophan hydroxylase 1 inhibitor | 0.031 0.003 DBMET00502 0.072 0.002 DBMET00494 | DBMET00494 | |
| 0.05 | 0.021 | 0.067 | Guanylate cyclase inhibitor | 0.067 0.006 DBMET00494 | DBMET00494 | |
| 0.037 | 0.009 | 0.037 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.036 0.009 DBMET00502 0.026 0.022 DBMET00494 | ||
| 0.064 | 0.036 | 0.064 | Beta 2 adrenoreceptor agonist | 0.062 0.042 DBMET00494 | ||
| 0.078 | 0.051 | 0.078 | Carbonic anhydrase XIII inhibitor | |||
| 0.067 | 0.04 | 0.185 | Neuraminidase (influenza) inhibitor | 0.185 0.005 DBMET00502 0.166 0.006 DBMET00494 | DBMET00502 | |
| 0.061 | 0.034 | 0.061 | Carbonic anhydrase VB inhibitor | |||
| 0.034 | 0.008 | 0.034 | Lysophosphatidic acid receptor 1 agonist | 0.025 0.017 DBMET00494 | ||
| 0.044 | 0.019 | 0.085 | Diamine oxidase inhibitor | 0.085 0.005 DBMET00502 | DBMET00502 | |
| 0.04 | 0.015 | 0.06 | Bradykinin B2 receptor antagonist | 0.06 0.004 DBMET00502 | DBMET00502 | |
| 0.105 | 0.08 | 0.105 | TRPA1 agonist | |||
| 0.052 | 0.028 | 0.052 | Collagenase inhibitor | 0.046 0.041 DBMET00502 | ||
| 0.068 | 0.044 | 0.068 | Carbonic anhydrase V inhibitor | |||
| 0.045 | 0.022 | 0.092 | Melanocortin 1 antagonist | 0.092 0.012 DBMET00502 0.036 0.028 DBMET00494 | DBMET00502 | |
| 0.063 | 0.04 | 0.186 | Neuraminidase inhibitor | 0.156 0.005 DBMET00502 0.186 0.004 DBMET00494 | DBMET00494 | |
| 0.049 | 0.026 | 0.114 | Nicotinic receptor alpha3 subunit antagonist | 0.114 0.009 DBMET00494 | DBMET00494 | |
| 0.027 | 0.005 | 0.027 | Somatostatin 2 agonist | 0.017 0.008 DBMET00502 0.027 0.005 DBMET00494 | ||
| 0.027 | 0.006 | 0.047 | Neuraminidase (Influenza B) inhibitor | 0.038 0.003 DBMET00502 0.047 0.003 DBMET00494 | DBMET00494 | |
| 0.033 | 0.012 | 0.033 | Vasopressin 1A agonist | 0.027 0.024 DBMET00502 | ||
| 0.055 | 0.035 | 0.055 | Matrix metalloproteinase 1 inhibitor | 0.051 0.038 DBMET00494 | ||
| 0.025 | 0.004 | 0.056 | Integrin alphaVbeta6 antagonist | 0.056 0.002 DBMET00502 0.019 0.006 DBMET00494 | DBMET00502 | |
| 0.052 | 0.032 | 0.187 | Urokinase inhibitor | 0.187 0.005 DBMET00502 | DBMET00502 | |
| 0.042 | 0.022 | 0.042 | Glucagon-like peptide 1 receptor antagonist | 0.04 0.025 DBMET00502 | ||
| 0.031 | 0.012 | 0.031 | Thyroid hormone agonist | |||
| 0.057 | 0.038 | 0.176 | Kallikrein 1 inhibitor | 0.176 0.005 DBMET00502 | DBMET00502 | |
| 0.039 | 0.02 | 0.039 | Retinoid X alpha receptor agonist | |||
| 0.025 | 0.006 | 0.025 | Ileal bile acid transport inhibitor | |||
| 0.025 | 0.007 | 0.025 | Toll-Like receptor 8 agonist | |||
| 0.025 | 0.007 | 0.025 | Dipeptidyl peptidase IX inhibitor | |||
| 0.069 | 0.05 | 0.098 | Protein kinase C beta inhibitor | 0.098 0.014 DBMET00494 | DBMET00494 | |
| 0.026 | 0.009 | 0.026 | Isoleucine-tRNA ligase inhibitor | |||
| 0.05 | 0.033 | 0.05 | Carbonic anhydrase XIV inhibitor | |||
| 0.039 | 0.021 | 0.039 | Glutamate (mGluR group II) agonist | 0.033 0.026 DBMET00494 | ||
| 0.026 | 0.01 | 0.026 | ICAM 1 antagonist | 0.026 0.01 DBMET00494 | ||
| 0.026 | 0.01 | 0.196 | Integrin beta5 antagonist | 0.196 0.004 DBMET00502 0.027 0.01 DBMET00494 | DBMET00502 | |
| 0.027 | 0.011 | 0.027 | Neurokinin 1 agonist | |||
| 0.036 | 0.019 | 0.036 | HCV polyprotein inhibitor | |||
| 0.022 | 0.006 | 0.022 | Telomerase stimulant | |||
| 0.049 | 0.033 | 0.049 | Dopamine beta hydroxylase inhibitor | |||
| 0.022 | 0.006 | 0.022 | Dipeptidyl peptidase VIII inhibitor | |||
| 0.021 | 0.006 | 0.022 | Carbonic anhydrase IV stimulant | 0.022 0.005 DBMET00502 | DBMET00502 | |
| 0.027 | 0.012 | 0.027 | Neutral endopeptidase inhibitor | |||
| 0.026 | 0.013 | 0.026 | Aminopeptidase P inhibitor | 0.025 0.014 DBMET00494 | ||
| 0.056 | 0.043 | 0.067 | Cathepsin L inhibitor | 0.067 0.032 DBMET00502 | DBMET00502 | |
| 0.032 | 0.019 | 0.127 | Factor VII inhibitor | 0.127 0.005 DBMET00502 | DBMET00502 | |
| 0.029 | 0.017 | 0.146 | NMDA 2D receptor antagonist | 0.028 0.018 DBMET00502 0.146 0.003 DBMET00494 | DBMET00494 | |
| 0.037 | 0.025 | 0.073 | Somatostatin 4 agonist | 0.033 0.032 DBMET00502 0.073 0.009 DBMET00494 | DBMET00494 | |
| 0.03 | 0.018 | 0.03 | Hypoxanthine phosphoribosyltransferase inhibitor | |||
| 0.02 | 0.008 | 0.028 | Glucagon agonist | 0.028 0.007 DBMET00502 | DBMET00502 | |
| 0.049 | 0.038 | 0.053 | Beta 2 adrenoreceptor antagonist | 0.053 0.033 DBMET00494 | DBMET00494 | |
| 0.032 | 0.021 | 0.032 | Methionyl aminopeptidase 1 inhibitor | |||
| 0.035 | 0.024 | 0.035 | Growth factor receptor-bound protein 2 antagonist | 0.032 0.031 DBMET00502 | ||
| 0.02 | 0.009 | 0.034 | KiSS-1 receptor antagonist | 0.034 0.004 DBMET00502 | DBMET00502 | |
| 0.02 | 0.009 | 0.02 | Methylmalonyl-CoA mutase inhibitor | 0.018 0.014 DBMET00494 | ||
| 0.052 | 0.042 | 0.052 | Thromboxane synthase inhibitor | |||
| 0.029 | 0.018 | 0.029 | 1,3-Beta-glucan synthase inhibitor | |||
| 0.059 | 0.048 | 0.059 | 5 Hydroxytryptamine 2A agonist | 0.057 0.05 DBMET00494 | ||
| 0.021 | 0.011 | 0.021 | Caspase 8 inhibitor | |||
| 0.056 | 0.046 | 0.078 | Cathepsin E inhibitor | 0.067 0.032 DBMET00502 0.078 0.024 DBMET00494 | DBMET00494 | |
| 0.08 | 0.07 | 0.08 | D-Ala-D-Ala ligase inhibitor | |||
| 0.015 | 0.005 | 0.128 | Integrin alphaVbeta5 antagonist | 0.128 0.002 DBMET00502 0.009 0.008 DBMET00494 | DBMET00502 | |
| 0.066 | 0.056 | 0.068 | CXC chemokine receptor antagonist | 0.068 0.053 DBMET00502 | DBMET00502 | |
| 0.073 | 0.064 | 0.266 | Acetylcholine nicotinic antagonist | 0.266 0.008 DBMET00494 | DBMET00494 | |
| 0.016 | 0.007 | 0.016 | Lysophosphatidic acid receptor 3 agonist | |||
| 0.052 | 0.043 | 0.073 | Sphingosine kinase 2 inhibitor | 0.073 0.019 DBMET00502 0.073 0.019 DBMET00494 | DBMET00494 | |
| 0.055 | 0.047 | 0.055 | Lipocortins synthesis agonist | |||
| 0.034 | 0.026 | 0.034 | Retinoid X receptor agonist | |||
| 0.019 | 0.011 | 0.021 | Angiotensin-converting enzyme 2 inhibitor | 0.021 0.008 DBMET00494 | DBMET00494 | |
| 0.044 | 0.036 | 0.044 | Glycine transporter inhibitor | |||
| 0.017 | 0.009 | 0.017 | Purinergic P2Y1 agonist | |||
| 0.038 | 0.03 | 0.038 | Aggrecanase 1 inhibitor | |||
| 0.014 | 0.007 | 0.014 | Carbonic anhydrase XI inhibitor | |||
| 0.045 | 0.038 | 0.048 | Bombesin antagonist | 0.048 0.033 DBMET00502 | DBMET00502 | |
| 0.019 | 0.012 | 0.019 | Antibiotic Anthracycline-like | |||
| 0.039 | 0.033 | 0.077 | Sphingosine kinase 1 inhibitor | 0.052 0.014 DBMET00502 0.077 0.005 DBMET00494 | DBMET00494 | |
| 0.01 | 0.004 | 0.01 | Phosphoribosylglycinamide formyltransferase inhibitor | 0.007 0.005 DBMET00502 | ||
| 0.096 | 0.09 | 0.125 | DNA polymerase I inhibitor | 0.125 0.065 DBMET00502 | DBMET00502 | |
| 0.136 | 0.13 | 0.136 | Pyruvate kinase inhibitor | |||
| 0.018 | 0.012 | 0.076 | Protease activated receptor agonist | 0.076 0.004 DBMET00502 | DBMET00502 | |
| 0.04 | 0.034 | 0.04 | Opioid kappa receptor agonist | |||
| 0.047 | 0.041 | 0.092 | Prolyl endopeptidase inhibitor | 0.092 0.008 DBMET00494 | DBMET00494 | |
| 0.032 | 0.027 | 0.035 | Angiotensin II receptor antagonist | 0.035 0.022 DBMET00494 | DBMET00494 | |
| 0.039 | 0.033 | 0.039 | Plasmepsin II inhibitor | |||
| 0.06 | 0.055 | 0.07 | Beta adrenoreceptor antagonist | 0.07 0.038 DBMET00494 | DBMET00494 | |
| 0.015 | 0.011 | 0.015 | Thromboxane A2 agonist | |||
| 0.021 | 0.017 | 0.025 | Vasopressin 1 agonist | 0.025 0.01 DBMET00502 | DBMET00502 | |
| 0.019 | 0.017 | 0.024 | Nociceptin (N/OFQ) receptor agonist | 0.024 0.013 DBMET00502 | DBMET00502 | |
| 0.007 | 0.004 | 0.02 | Integrin alpha5beta6 antagonist | 0.02 0.002 DBMET00502 0.008 0.004 DBMET00494 | DBMET00502 | |
| 0.018 | 0.015 | 0.018 | Granulocyte colony stimulating factor receptor agonist | |||
| 0.041 | 0.039 | 0.041 | Farnesyltransferase inhibitor | |||
| 0.004 | 0.002 | 0.009 | Bradykinin B1 receptor agonist | 0.009 0.001 DBMET00502 | DBMET00502 | |
| 0.034 | 0.032 | 0.189 | Factor VIIa inhibitor | 0.189 0.005 DBMET00502 | DBMET00502 | |
| 0.032 | 0.03 | 0.032 | Cholecystokinin A antagonist | |||
| 0.054 | 0.053 | 0.059 | Purinergic P2X1 antagonist | 0.059 0.045 DBMET00494 | DBMET00494 | |
| 0.011 | 0.009 | 0.031 | Protease activated receptor 1 agonist | 0.031 0.004 DBMET00502 | DBMET00502 | |
| 0.024 | 0.023 | 0.26 | Melanocortin 3 antagonist | 0.26 0.005 DBMET00502 | DBMET00502 | |
| 0.019 | 0.018 | 0.019 | Retinoid X beta receptor antagonist | |||
| 0.038 | 0.037 | 0.043 | Angiotensin AT1 receptor antagonist | 0.043 0.027 DBMET00494 | DBMET00494 | |
| 0.02 | 0.019 | 0.02 | Geranylgeranyltransferase inhibitor | |||
| 0.011 | 0.01 | 0.011 | Calcium-dependent phospholipase A2 inhibitor | |||
| 0.081 | 0.081 | 0.095 | Polo-like kinase-1 inhibitor | 0.095 0.053 DBMET00494 | DBMET00494 | |
| 0.049 | 0.05 | 0.059 | Cathepsin B inhibitor | 0.059 0.037 DBMET00502 | DBMET00502 | |
| 0.06 | 0.06 | 0.064 | Potassium channel large-conductance Ca-activated activator | 0.064 0.052 DBMET00494 | DBMET00494 | |
| 0.021 | 0.024 | 0.083 | Melanocortin 5 antagonist | 0.083 0.009 DBMET00502 | DBMET00502 | |
| 0.01 | 0.013 | 0.021 | Integrin beta2 antagonist | 0.021 0.005 DBMET00494 | DBMET00494 | |
| 0.024 | 0.028 | 0.03 | Antidiuretic hormone agonist | 0.03 0.014 DBMET00502 | DBMET00502 | |
| 0.008 | 0.012 | 0.016 | Angiotensin AT2 receptor agonist | 0.016 0.004 DBMET00502 | DBMET00502 | |
| 0.115 | 0.12 | 0.148 | Protein-tyrosine phosphatase inhibitor | 0.148 0.08 DBMET00494 | DBMET00494 | |
| 0.008 | 0.013 | 0.02 | Melatonin 5 antagonist | 0.02 0.004 DBMET00502 | DBMET00502 | |
| 0.025 | 0.031 | 0.027 | Lysophosphatidic acid 2 receptor antagonist | 0.027 0.026 DBMET00494 | DBMET00494 | |
| 0.069 | 0.076 | 0.075 | Sphingosine 1-phosphate receptor antagonist | 0.075 0.057 DBMET00494 | DBMET00494 | |
| 0.03 | 0.038 | 0.082 | Nicotinic receptor beta4 subunit antagonist | 0.082 0.008 DBMET00494 | DBMET00494 | |
| 0.035 | 0.043 | 0.093 | Phenylethanolamine N methyltransferase inhibitor | 0.093 0.003 DBMET00494 | DBMET00494 | |
| 0.038 | 0.047 | 0.057 | Glutamate (mGluR group I) agonist | 0.057 0.025 DBMET00494 | DBMET00494 | |
| 0.041 | 0.052 | 0.049 | Beta adrenoreceptor agonist | 0.049 0.02 DBMET00494 | DBMET00494 | |
| 0.018 | 0.028 | 0.023 | Beta 1 adrenoreceptor agonist | 0.023 0.014 DBMET00494 | DBMET00494 | |
| 0.005 | 0.017 | 0.012 | KiSS-1 receptor agonist | 0.012 0.005 DBMET00502 | DBMET00502 | |
| 0.017 | 0.028 | 0.022 | Prostaglandin H2 antagonist | 0.022 0.021 DBMET00494 | DBMET00494 | |
| 0.105 | 0.118 | 0.117 | Nav1.6 sodium channel blocker | 0.117 0.1 DBMET00502 | DBMET00502 | |
| 0.129 | 0.143 | 0.139 | Lipocortins synthesis antagonist | 0.139 0.123 DBMET00494 | DBMET00494 | |
| 0.022 | 0.036 | 0.069 | Trypsin II inhibitor | 0.069 0.006 DBMET00502 | DBMET00502 | |
| 0.015 | 0.03 | 0.021 | Somatostatin 3 agonist | 0.021 0.009 DBMET00494 | DBMET00494 | |
| 0.011 | 0.026 | 0.212 | Melanocortin 1 agonist | 0.212 0.004 DBMET00502 | DBMET00502 | |
| 0.009 | 0.024 | 0.101 | Melanocortin 3 agonist | 0.101 0.005 DBMET00502 | DBMET00502 | |
| 0.013 | 0.03 | 0.132 | Melanocortin agonist | 0.132 0.006 DBMET00502 | DBMET00502 | |
| 0.007 | 0.023 | 0.133 | Melanocortin 5 agonist | 0.133 0.005 DBMET00502 | DBMET00502 | |
| 0.016 | 0.033 | 0.035 | Methionyl aminopeptidase 2 inhibitor | 0.035 0.011 DBMET00494 | DBMET00494 | |
| 0.022 | 0.039 | 0.029 | Motilin receptor antagonist | 0.029 0.017 DBMET00494 | DBMET00494 | |
| 0.083 | 0.101 | 0.177 | AMP-activated protein kinase stimulant | 0.177 0.015 DBMET00502 0.089 0.088 DBMET00494 | DBMET00502 | |
| 0.021 | 0.04 | 0.029 | Dipeptidyl peptidase I inhibitor | 0.029 0.023 DBMET00494 | DBMET00494 | |
| 0.021 | 0.04 | 0.035 | Complement C5a chemotactic receptor antagonist | 0.035 0.015 DBMET00502 | DBMET00502 | |
| 0.012 | 0.032 | 0.078 | Melanocortin 4 agonist | 0.078 0.007 DBMET00502 | DBMET00502 | |
| 0.086 | 0.107 | 0.106 | Cholesterol synthesis inhibitor | 0.106 0.079 DBMET00494 | DBMET00494 | |
| 0.021 | 0.042 | 0.024 | Complement factor 1s inhibitor | 0.024 0.022 DBMET00502 | DBMET00502 | |
| 0.05 | 0.071 | 0.241 | Neuronal nicotinic receptor antagonist | 0.241 0.007 DBMET00494 | DBMET00494 | |
| 0.054 | 0.077 | 0.066 | Beta 3 adrenoreceptor antagonist | 0.066 0.04 DBMET00494 | DBMET00494 | |
| 0.021 | 0.046 | 0.03 | Glutamate (mGluR2) antagonist | 0.03 0.02 DBMET00494 | DBMET00494 | |
| 0.062 | 0.087 | 0.111 | Adrenaline agonist | 0.111 0.03 DBMET00494 | DBMET00494 | |
| 0.039 | 0.064 | 0.085 | Histamine agonist | 0.085 0.012 DBMET00502 | DBMET00502 | |
| 0.044 | 0.07 | 0.058 | Collagenase 3 inhibitor | 0.058 0.044 DBMET00494 | DBMET00494 | |
| 0.026 | 0.053 | 0.042 | Ceramide glucosyltransferase inhibitor | 0.042 0.014 DBMET00494 | DBMET00494 | |
| 0.009 | 0.037 | 0.016 | Vasopressin 2 agonist | 0.016 0.013 DBMET00502 | DBMET00502 | |
| 0.038 | 0.066 | 0.051 | Cathepsin D inhibitor | 0.051 0.04 DBMET00502 | DBMET00502 | |
| 0.013 | 0.042 | 0.062 | NMDA receptor glycine site antagonist | 0.062 0.005 DBMET00494 | DBMET00494 | |
| 0.032 | 0.061 | 0.083 | Kallikrein inhibitor | 0.083 0.014 DBMET00502 | DBMET00502 | |
| 0.022 | 0.051 | 0.039 | Cathepsin L2 inhibitor | 0.039 0.029 DBMET00502 | DBMET00502 | |
| 0.03 | 0.059 | 0.057 | Leukocyte elastase inhibitor | 0.057 0.02 DBMET00494 | DBMET00494 | |
| 0.024 | 0.054 | 0.039 | RNA-directed RNA polymerase inhibitor | 0.039 0.019 DBMET00494 | DBMET00494 | |
| 0.01 | 0.042 | 0.022 | Histamine H4 receptor agonist | 0.022 0.01 DBMET00502 | DBMET00502 | |
| 0.048 | 0.081 | 0.113 | Gonadotropin-releasing hormone receptor agonist | 0.113 0.007 DBMET00502 | DBMET00502 | |
| 0.074 | 0.113 | 0.091 | Protein-tyrosine phosphatase 1B inhibitor | 0.091 0.088 DBMET00494 | DBMET00494 | |
| 0.007 | 0.048 | 0.156 | Melatonin 3 antagonist | 0.156 0.004 DBMET00502 | DBMET00502 | |
| 0.048 | 0.092 | 0.068 | Ryanodine receptor antagonist | 0.068 0.021 DBMET00494 | DBMET00494 | |
| 0.039 | 0.086 | 0.119 | Protease activated receptor antagonist | 0.119 0.009 DBMET00502 | DBMET00502 | |
| 0.035 | 0.081 | 0.063 | Baculoviral IAP repeat-containing protein inhibitor | 0.063 0.005 DBMET00494 | DBMET00494 | |
| 0.024 | 0.073 | 0.049 | Protein kinase (CK2) beta inhibitor | 0.049 0.008 DBMET00494 | DBMET00494 | |
| 0.039 | 0.087 | 0.063 | Factor III inhibitor | 0.063 0.015 DBMET00502 0.052 0.03 DBMET00494 | DBMET00502 | |
| 0.051 | 0.103 | 0.088 | Secretase beta inhibitor | 0.088 0.027 DBMET00502 | DBMET00502 | |
| 0.014 | 0.068 | 0.031 | Nicotinic acid receptor 2 antagonist | 0.031 0.011 DBMET00494 | DBMET00494 | |
| 0.023 | 0.079 | 0.038 | ADAM10 endopeptidase inhibitor | 0.038 0.017 DBMET00494 | DBMET00494 | |
| 0.012 | 0.07 | 0.023 | Protease (Human cytomegalovirus) inhibitor | 0.023 0.013 DBMET00494 | DBMET00494 | |
| 0.007 | 0.068 | 0.021 | Angiotensin AT2 receptor antagonist | 0.021 0.015 DBMET00494 | DBMET00494 | |
| 0.017 | 0.079 | 0.026 | Thymidine phosphorylase inhibitor | 0.026 0.019 DBMET00494 | DBMET00494 | |
| 0.016 | 0.082 | 0.033 | Epoxide hydrolase 1 inhibitor | 0.033 0.018 DBMET00494 | DBMET00494 | |
| 0.015 | 0.082 | 0.035 | Free fatty acid receptor 1 antagonist | 0.035 0.022 DBMET00494 | DBMET00494 | |
| 0.017 | 0.084 | 0.045 | Carnitine palmitoyltransferase inhibitor | 0.045 0.011 DBMET00494 | DBMET00494 | |
| 0.008 | 0.077 | 0.02 | Complement factor D inhibitor | 0.02 0.009 DBMET00494 | DBMET00494 | |
| 0.037 | 0.107 | 0.072 | Glucosylceramidase inhibitor | 0.072 0.021 DBMET00494 | DBMET00494 | |
| 0.041 | 0.114 | 0.055 | Pregnane X receptor antagonist | 0.055 0.043 DBMET00494 | DBMET00494 | |
| 0.017 | 0.09 | 0.045 | Carnitine palmitoyltransferase 1 inhibitor | 0.045 0.011 DBMET00494 | DBMET00494 | |
| 0.015 | 0.089 | 0.024 | 5 Hydroxytryptamine 4 agonist | 0.024 0.017 DBMET00494 | DBMET00494 | |
| 0.029 | 0.107 | 0.059 | Acetylcholine M3 receptor antagonist | 0.059 0.042 DBMET00494 | DBMET00494 | |
| 0.015 | 0.097 | 0.099 | Factor Xa inhibitor | 0.099 0.014 DBMET00502 | DBMET00502 | |
| 0.011 | 0.096 | 0.048 | Bradykinin antagonist | 0.048 0.016 DBMET00502 | DBMET00502 | |
| 0.024 | 0.108 | 0.048 | Nerve growth factor antagonist | 0.048 0.021 DBMET00494 | DBMET00494 | |
| 0.065 | 0.152 | 0.082 | CC chemokine 5 receptor agonist | 0.082 0.059 DBMET00494 | DBMET00494 | |
| 0.01 | 0.098 | 0.032 | HCV NS5B polymerase inhibitor | 0.032 0.021 DBMET00494 | DBMET00494 | |
| 0.039 | 0.131 | 0.158 | Nicotinic alpha4beta2 receptor antagonist | 0.158 0.007 DBMET00494 | DBMET00494 | |
| 0.025 | 0.12 | 0.062 | CC chemokine 4 receptor antagonist | 0.062 0.015 DBMET00494 | DBMET00494 | |
| 0.036 | 0.132 | 0.062 | 5 Hydroxytryptamine 3 agonist | 0.062 0.045 DBMET00502 0.06 0.048 DBMET00494 | DBMET00502 | |
| 0.022 | 0.119 | 0.376 | Dihydroorotase inhibitor | 0.376 0.002 DBMET00494 | DBMET00494 | |
| 0.011 | 0.11 | 0.048 | Gonadotropin-releasing hormone receptor antagonist | 0.048 0.017 DBMET00502 0.031 0.027 DBMET00494 | DBMET00502 | |
| 0.051 | 0.153 | 0.088 | Protein kinase C delta inhibitor | 0.088 0.066 DBMET00494 | DBMET00494 | |
| 0.014 | 0.118 | 0.031 | 5 Hydroxytryptamine 6 agonist | 0.031 0.015 DBMET00494 | DBMET00494 | |
| 0.06 | 0.169 | 0.123 | Nav1.3 sodium channel blocker | 0.123 0.07 DBMET00494 | DBMET00494 | |
| 0.009 | 0.119 | 0.036 | Plasma kallikrein inhibitor | 0.036 0.022 DBMET00502 | DBMET00502 | |
| 0.186 | 0.298 | 0.544 | Calcium channel L-type activator | 0.544 0.014 DBMET00494 | DBMET00494 | |
| 0.025 | 0.138 | 0.132 | Nicotinic receptor alpha7 subunit antagonist | 0.132 0.008 DBMET00494 | DBMET00494 | |
| 0.049 | 0.163 | 0.114 | Histamine H2 receptor antagonist | 0.114 0.024 DBMET00502 | DBMET00502 | |
| 0.006 | 0.123 | 0.095 | Factor X inhibitor | 0.095 0.011 DBMET00502 | DBMET00502 | |
| 0.018 | 0.135 | 0.04 | Retinoic acid alpha receptor agonist | 0.04 0.025 DBMET00494 | DBMET00494 | |
| 0.031 | 0.15 | 0.138 | Nicotinic alpha3beta2 receptor antagonist | 0.138 0.004 DBMET00494 | DBMET00494 | |
| 0.119 | 0.239 | 0.24 | 5 Hydroxytryptamine 1E antagonist | 0.24 0.086 DBMET00494 | DBMET00494 | |
| 0.031 | 0.163 | 0.061 | Dihydroorotate oxidase inhibitor | 0.061 0.028 DBMET00494 | DBMET00494 | |
| 0.045 | 0.179 | 0.109 | Neuropeptide Y antagonist | 0.109 0.035 DBMET00502 | DBMET00502 | |
| 0.057 | 0.196 | 0.22 | Nav1.1 sodium channel blocker | 0.22 0.015 DBMET00502 | DBMET00502 | |
| 0.027 | 0.166 | 0.057 | Factor IXa inhibitor | 0.057 0.029 DBMET00502 | DBMET00502 | |
| 0.022 | 0.163 | 0.069 | Dopamine uptake inhibitor | 0.069 0.031 DBMET00494 | DBMET00494 | |
| 0.047 | 0.188 | 0.076 | Caspase 7 inhibitor | 0.076 0.072 DBMET00494 | DBMET00494 | |
| 0.053 | 0.195 | 0.095 | mTOR complex 2 inhibitor | 0.095 0.039 DBMET00494 | DBMET00494 | |
| 0.005 | 0.147 | 0.037 | Growth hormone secretagogue receptor agonist | 0.037 0.023 DBMET00494 | DBMET00494 | |
| 0.025 | 0.168 | 0.078 | Androgen agonist | 0.078 0.025 DBMET00494 | DBMET00494 | |
| 0.006 | 0.161 | 0.05 | Nicotinic alpha4beta2 receptor agonist | 0.05 0.004 DBMET00494 | DBMET00494 | |
| 0.004 | 0.164 | 0.026 | Nicotinic alpha4 receptor agonist | 0.026 0.005 DBMET00494 | DBMET00494 | |
| 0.063 | 0.234 | 0.137 | Interleukin 4 antagonist | 0.137 0.064 DBMET00502 | DBMET00502 | |
| 0.023 | 0.195 | 0.086 | Acetylcholine M4 receptor antagonist | 0.086 0.04 DBMET00494 | DBMET00494 | |
| 0.034 | 0.207 | 0.073 | Potassium channel (Tandem pore domain) blocker | 0.073 0.052 DBMET00494 | DBMET00494 | |
| 0.008 | 0.185 | 0.047 | Factor XI inhibitor | 0.037 0.019 DBMET00502 0.047 0.011 DBMET00494 | DBMET00494 | |
| 0.143 | 0.324 | 0.577 | Analgesic | 0.577 0.031 DBMET00494 | DBMET00494 | |
| 0.06 | 0.241 | 0.099 | Acetylcholine release stimulant | 0.099 0.091 DBMET00494 | DBMET00494 | |
| 0.006 | 0.189 | 0.045 | Nicotinic alpha3beta4 receptor agonist | 0.045 0.007 DBMET00494 | DBMET00494 | |
| 0.015 | 0.2 | 0.06 | Acetylcholine M5 receptor antagonist | 0.06 0.042 DBMET00494 | DBMET00494 | |
| 0.021 | 0.217 | 0.052 | DNA gyrase subunit A inhibitor | 0.052 0.015 DBMET00494 | DBMET00494 | |
| 0.078 | 0.294 | 0.146 | 3C-like protease (Human coronavirus) inhibitor | 0.146 0.108 DBMET00494 | DBMET00494 | |
| 0.076 | 0.292 | 0.173 | Tumour necrosis factor antagonist | 0.173 0.073 DBMET00494 | DBMET00494 | |
| 0.01 | 0.239 | 0.058 | Factor XIa inhibitor | 0.058 0.013 DBMET00494 | DBMET00494 | |
| 0.05 | 0.279 | 0.096 | Nav1.5 sodium channel blocker | 0.096 0.092 DBMET00502 | DBMET00502 | |
| 0.08 | 0.32 | 0.301 | Cardiotonic | 0.301 0.055 DBMET00502 | DBMET00502 | |
| 0.051 | 0.299 | 0.09 | 3C-Like protease (SARS coronavirus) inhibitor | 0.09 0.047 DBMET00494 | DBMET00494 | |
| 0.008 | 0.273 | 0.033 | Baculoviral IAP repeat-containing protein 3 inhibitor | 0.033 0.004 DBMET00494 | DBMET00494 | |
| 0.005 | 0.287 | 0.037 | Acetylcholine M1 receptor agonist | 0.037 0.036 DBMET00494 | DBMET00494 | |
| 0.012 | 0.3 | 0.056 | Cyclin-dependent kinase 6 inhibitor | 0.056 0.045 DBMET00494 | DBMET00494 | |
| 0.008 | 0.307 | 0.058 | Acetylcholine muscarinic agonist | 0.058 0.035 DBMET00494 | DBMET00494 | |
| 0.058 | 0.364 | 0.129 | Interleukin 2 antagonist | 0.129 0.033 DBMET00502 | DBMET00502 | |
| 0.014 | 0.34 | 0.078 | Myc inhibitor | 0.078 0.014 DBMET00494 | DBMET00494 | |
| 0.006 | 0.335 | 0.034 | Motilin receptor agonist | 0.034 0.008 DBMET00494 | DBMET00494 | |
| 0.014 | 0.351 | 0.135 | Acetylcholine nicotinic agonist | 0.135 0.021 DBMET00494 | DBMET00494 | |
| 0.004 | 0.348 | 0.042 | Sodium/hydrogen exchanger inhibitor | 0.042 0.004 DBMET00502 | DBMET00502 | |
| 0.028 | 0.372 | 0.067 | Kallikrein 7 inhibitor | 0.067 0.034 DBMET00502 | DBMET00502 | |
| 0.01 | 0.359 | 0.058 | Dopamine transporter inhibitor | 0.058 0.026 DBMET00494 | DBMET00494 | |
| 0.018 | 0.37 | 0.043 | Glucose-6-phosphate dehydrogenase inhibitor | 0.043 0.018 DBMET00494 | DBMET00494 | |
| 0.008 | 0.372 | 0.064 | Dihydroorotate dehydrogenase inhibitor | 0.064 0.025 DBMET00494 | DBMET00494 | |
| 0.007 | 0.394 | 0.102 | Nicotinic receptor alpha4 subunit antagonist | 0.102 0.008 DBMET00494 | DBMET00494 | |
| 0.005 | 0.399 | 0.049 | 5 Hydroxytryptamine 2C agonist | 0.049 0.028 DBMET00494 | DBMET00494 | |
| 0.013 | 0.408 | 0.123 | Acetylcholine agonist | 0.123 0.035 DBMET00494 | DBMET00494 | |
| 0.051 | 0.485 | 0.187 | Angiogenesis inhibitor | 0.187 0.185 DBMET00502 | DBMET00502 | |
| 0.006 | 0.462 | 0.049 | Nicotinic neuronal receptor agonist | 0.049 0.047 DBMET00494 | DBMET00494 | |
| 0.027 | 0.51 | 0.065 | Heme oxygenase stimulant | 0.065 0.033 DBMET00494 | DBMET00494 | |
| 0.043 | 0.565 | 0.332 | Antiobesity | 0.332 0.096 DBMET00494 | DBMET00494 | |
| 0.007 | 0.541 | 0.105 | Check point kinase 2 inhibitor | 0.105 0.061 DBMET00494 | DBMET00494 | |
| 0.01 | 0.618 | 0.095 | MAP-kinase-activated kinase 2 inhibitor | 0.095 0.031 DBMET00494 | DBMET00494 | |
| 0.012 | 0.621 | 0.103 | MAP-kinase-activated kinase inhibitor | 0.103 0.036 DBMET00494 | DBMET00494 | |
| 0.093 | 0.701 | 0.195 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.195 0.179 DBMET00494 | DBMET00494 | |
| 0.035 | 0.669 | 0.264 | Sigma receptor agonist | 0.264 0.046 DBMET00502 | DBMET00502 | |
| 0.014 | 0.66 | 0.064 | CC chemokine receptor 2B antagonist | 0.064 0.015 DBMET00494 | DBMET00494 | |
| 0.04 | 0.713 | 0.137 | MAP kinase kinase 4 inhibitor | 0.137 0.094 DBMET00494 | DBMET00494 | |
| 0.063 | 0.744 | 0.335 | Ca(v)3.3 blocker | 0.335 0.02 DBMET00502 | DBMET00502 | |
| 0.003 | 0.686 | 0.01 | Baculoviral IAP repeat-containing protein 2 inhibitor | 0.01 0.005 DBMET00494 | DBMET00494 | |
| 0.064 | 0.755 | 0.121 | CC chemokine 6 receptor antagonist | 0.121 0.111 DBMET00494 | DBMET00494 | |
| 0.013 | 0.704 | 0.092 | Acetylcholine M3 receptor agonist | 0.092 0.05 DBMET00494 | DBMET00494 | |
| 0.019 | 0.733 | 0.12 | MAP3K9 inhibitor | 0.12 0.113 DBMET00494 | DBMET00494 | |
| 0.002 | 0.802 | 0.021 | Prokineticin receptor 1 antagonist | 0.021 0.005 DBMET00502 | DBMET00502 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |